Insulin Therapy Center

For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …

For many people living with diabetes, gaining access to an automated insulin delivery (AID) system can be life-changing. These technologies help improve glycemic outcomes, reduce hypoglycemia risk, and ease the daily burden of diabetes management. Yet despite their proven benefits, many patients continue to face lengthy delays before gaining access. …

For many people living with diabetes, insulin is more than a medication—it is a lifeline. Yet despite its critical role, some patients stop taking insulin without informing their healthcare provider. The reasons vary widely and may include medication costs, treatment fatigue, fear of side effects, weight gain concerns, or misunderstandings …

Many healthcare providers focus heavily on daytime glucose control, yet some of the most dangerous hypoglycemic episodes occur while patients are asleep. Despite major advances in insulin therapy and glucose monitoring, nocturnal hypoglycemia remains a significant clinical concern for people living with diabetes. Because symptoms often go unnoticed during sleep, …

Patients treated with corticosteroids for asthma, COPD exacerbations, rheumatologic disease, inflammatory bowel disease, or cancer-related complications often develop significant elevations in blood glucose. In many cases, these patients have no prior history of diabetes. Yet within days of therapy initiation, blood glucose levels can rise dramatically, creating a challenging clinical …

For years, diabetes care has relied on one key rule: insulin should be given before meals whenever possible. Yet many people living with diabetes still struggle with timing. Busy schedules, unpredictable eating habits, and delayed dosing often lead to postprandial glucose spikes. Now, with the rise of ultra-rapid insulin AID …

Automated insulin delivery for people with type 2 diabetes is entering a new phase. What once seemed reserved for highly specialized endocrinology clinics is now moving steadily into primary care offices across the country. Following the updated 2026 American Diabetes Association Standards of Care and recent FDA clearances, more adults …

A patient arrives at the pharmacy expecting their usual insulin refill, only to discover the box, brand name, and pen device suddenly look different. The pharmacist explains that the medication is an interchangeable biosimilar approved for automatic substitution. Although the insulin is considered clinically equivalent, the unexpected switch can still …

The arrival of a once-weekly basal insulin option marks one of the most meaningful advances in insulin therapy in decades. For years, daily basal injections have been the standard of care for people with type 1 and type 2 diabetes. However, many patients struggle with adherence, missed doses, and therapeutic …

Could the conventional “lifelong treatment” model for type 2 diabetes be rethought? Recent trials suggest that short‑term intensive therapy may offer more than transient glycemic control—it might trigger lasting remission in newly diagnosed patients. Such interventions, combining aggressive pharmacologic therapy or insulin with lifestyle change, show potential to preserve β‑cell …